Product Name | Tamoxifen Citrate |
Description |
Autophagy inducer |
Purity | >99% |
CAS No. | 54965-24-1 |
Molecular Formula | C26H29NO•C6H8O7 |
Molecular Weight | 563.65 |
Field of Use | Not for use in humans. Not for use in diagnostics or therapeutics. For in vitro research use only. |
Storage Temperature | -20ºC |
Shipping Temperature | Shipped Ambient |
Product Type | Inducer |
Solubility | Soluble in methanol (50 mg/ml) or ethanol; very slightly soluble in water or acetone. |
Source | Synthetic |
Appearance | White to off-white powder |
SMILES | C(C(O)(C(=O)O)CC(=O)O)C(=O)O.C3=C(C(=C(C1=CC=CC=C1)CC)C2=CC=CC=C2)C=CC(=C3)OCCN(C)C |
InChI | InChI=1S/C26H29NO.C6H8O7/c1-4-25(21-11-7-5-8-12-21)26(22-13-9-6-10-14-22)23-15-17-24(18-16-23)28-20-19-27(2)3;7-3(8)1-6(13,5(11)12)2-4(9)10/h5-18H,4,19-20H2,1-3H3;13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)/b |
InChIKey | FQZYTYWMLGAPFJ-OQKDUQJOSA-N |
Safety Phrases |
Classification: D2A- Very Toxic Material Causing Other Toxic Effects, Teratogen, Carcinogen, Reproductive hazard Safety Phrases: S22 - Do not breathe dust. S24/25 - Avoid contact with skin and eyes. S36/37/39 - Wear suitable protective clothing, gloves and eye/face protection. Hazard statements: H302- Harmful if swallowed. H350- May cause cancer. H360- May damage fertility or the unborn child. Precautionary statements: P201- Obtain special instructions before use. P308 + P313- IF exposed or concerned: Get medical advice/ attention. |
Cite This Product | Tamoxifen Citrate (StressMarq Biosciences Inc., Victoria BC CANADA, Catalog # SIH-389) |
Alternative Names | (2)-2-[4-(1,2-Diphenyl-1-butenyl)phenoxy]-N,N-dimethylethanamine citrate |
Research Areas | Autophagy, Cancer |
PubChem ID | 2733525 |
Scientific Background | Tamoxifen citrate is an endocrine therapy drug used to treat breast cancer. It acts to interrupt estrogen signaling by blocking the estrogen receptor (ER). In vivo, tamoxifen and tamoxafin metabolites bind to estrogen receptors, causing the transcription of estrogen-response genes to be inhibited. In vitro, Tamoxifen is known to inhibit protein kinase C through estrogen receptor-independent antineoplastic effects. This drug therefore has important applications in breast cancer research, particularly in ER+ breast cancers. Recent studies have shown tamoxifen-resistant cells use autophagy as a survival mechanism. |
References |
1. Thomas, S. et al. (2011). Breast Cancer Res Treat, 130(2): 437-47. 2. Ma, J. et al. (2014). BMC Cancer, 14: 172. 3. Patel, S. et al. (2012). Int J Radiat Oncol Biol Phys, 82(2): 739-42. 4. Wang, D. et al. (2004). Mol Endocrinol. 402-11. |
Reviews
There are no reviews yet.